BACKGROUND: Treatment of severely ill COVID-19 patients requires simultaneous management of oxygenation and inflammation without compromising viral clearance. While multiple tools are available to aid oxygenation, data supporting immune biomarkers for monitoring the host-pathogen interaction across disease stages and for titrating immunomodulatory therapy is lacking. METHODS: In this single-center cohort study, we used an immunoassay platform that enables rapid and quantitative measurement of interferon γ-induced protein 10 (IP-10), a host protein involved in lung injury from virus-induced hyperinflammation. A dynamic clinical decision support protocol was followed to manage patients infected with severe acute respiratory syndrome coronavirus 2 and examine the potential utility of timely and serial measurements of IP-10 as tool in regulating inflammation. RESULTS: Overall, 502 IP-10 measurements were performed on 52 patients between 7 April and 10 May 2020, with 12 patients admitted to the intensive care unit. IP-10 levels correlated with COVID-19 severity scores and admission to the intensive care unit. Among patients in the intensive care unit, the number of days with IP-10 levels exceeding 1,000 pg/mL was associated with mortality. Administration of corticosteroid immunomodulatory therapy decreased IP-10 levels significantly. Only two patients presented with subsequent IP-10 flare-ups exceeding 1,000 pg/mL and died of COVID-19-related complications. CONCLUSIONS: Serial and readily available IP-10 measurements potentially represent an actionable aid in managing inflammation in COVID-19 patients and therapeutic decision-making. TRIAL REGISTRATION: Clinicaltrials.gov, NCT04389645, retrospectively registered on May 15, 2020.
BACKGROUND: Treatment of severely illCOVID-19patients requires simultaneous management of oxygenation and inflammation without compromising viral clearance. While multiple tools are available to aid oxygenation, data supporting immune biomarkers for monitoring the host-pathogen interaction across disease stages and for titrating immunomodulatory therapy is lacking. METHODS: In this single-center cohort study, we used an immunoassay platform that enables rapid and quantitative measurement of interferon γ-induced protein 10 (IP-10), a host protein involved in lung injury from virus-induced hyperinflammation. A dynamic clinical decision support protocol was followed to manage patientsinfected with severe acute respiratory syndrome coronavirus 2 and examine the potential utility of timely and serial measurements of IP-10 as tool in regulating inflammation. RESULTS: Overall, 502 IP-10 measurements were performed on 52 patients between 7 April and 10 May 2020, with 12 patients admitted to the intensive care unit. IP-10 levels correlated with COVID-19 severity scores and admission to the intensive care unit. Among patients in the intensive care unit, the number of days with IP-10 levels exceeding 1,000 pg/mL was associated with mortality. Administration of corticosteroid immunomodulatory therapy decreased IP-10 levels significantly. Only two patients presented with subsequent IP-10 flare-ups exceeding 1,000 pg/mL and died of COVID-19-related complications. CONCLUSIONS: Serial and readily available IP-10 measurements potentially represent an actionable aid in managing inflammation in COVID-19patients and therapeutic decision-making. TRIAL REGISTRATION: Clinicaltrials.gov, NCT04389645, retrospectively registered on May 15, 2020.
Authors: María C Martín; Aurora Jurado; Cristina Abad-Molina; Antonio Orduña; Oscar Yarce; Ana M Navas; Vanesa Cunill; Danilo Escobar; Francisco Boix; Sergio Burillo-Sanz; María C Vegas-Sánchez; Yesenia Jiménez-de Las Pozas; Josefa Melero; Marta Aguilar; Oana Irina Sobieschi; Marcos López-Hoyos; Gonzalo Ocejo-Vinyals; David San Segundo; Delia Almeida; Silvia Medina; Luis Fernández; Esther Vergara; Bibiana Quirant; Eva Martínez-Cáceres; Marc Boiges; Marta Alonso; Laura Esparcia-Pinedo; Celia López-Sanz; Javier Muñoz-Vico; Serafín López-Palmero; Antonio Trujillo; Paula Álvarez; Álvaro Prada; David Monzón; Jesús Ontañón; Francisco M Marco; Sergio Mora; Ricardo Rojo; Gema González-Martínez; María T Martínez-Saavedra; Juana Gil-Herrera; Sergi Cantenys-Molina; Manuel Hernández; Janire Perurena-Prieto; Beatriz Rodríguez-Bayona; Alba Martínez; Esther Ocaña; Juan Molina Journal: Immun Ageing Date: 2021-05-20 Impact factor: 6.400
Authors: Gema M Olivarria; Yuting Cheng; Susana Furman; Collin Pachow; Lindsay A Hohsfield; Charlene Smith-Geater; Ricardo Miramontes; Jie Wu; Mara S Burns; Kate I Tsourmas; Jennifer Stocksdale; Cynthia Manlapaz; William H Yong; John Teijaro; Robert Edwards; Kim N Green; Leslie M Thompson; Thomas E Lane Journal: bioRxiv Date: 2021-11-17
Authors: Lowell Ling; Zigui Chen; Grace Lui; Chun Kwok Wong; Wai Tat Wong; Rita W Y Ng; Eugene Y K Tso; Kitty S C Fung; Veronica Chan; Apple C M Yeung; David S C Hui; Paul K S Chan Journal: Front Immunol Date: 2021-12-06 Impact factor: 7.561
Authors: Gema M Olivarria; Yuting Cheng; Susana Furman; Collin Pachow; Lindsay A Hohsfield; Charlene Smith-Geater; Ricardo Miramontes; Jie Wu; Mara S Burns; Kate I Tsourmas; Jennifer Stocksdale; Cynthia Manlapaz; William H Yong; John Teijaro; Robert Edwards; Kim N Green; Leslie M Thompson; Thomas E Lane Journal: J Virol Date: 2021-12-22 Impact factor: 5.103